Newsroom
Sorted by: Latest
-
TotalEnergies SE UK Regulatory Announcement: Transaction in Own Shares
PARIS--(BUSINESS WIRE)-- In accordance with the authorizations given by the shareholders’ general meeting on May 23, 2025, to trade on its shares and pursuant to applicable law on share repurchase, TotalEnergies SE (LEI: 529900S21EQ1BO4ESM68) (Paris:TTE) (LSE:TTE) (NYSE:TTE) declares the following purchases of its own shares (FR0000120271) from December 1 to December 5, 2025: Transaction Date Total daily volume (number of shares) Daily weighted average purchase price of shares (EUR/share) Amou...
-
Une étude révèle que l’IA ne transformera pas la mobilité sans une collaboration sans précédent
RIYAD, Arabie saoudite--(BUSINESS WIRE)--L’intelligence artificielle est en train de remodeler discrètement les systèmes de transport mondiaux, mais la plupart des déploiements restent des projets pilotes isolés qui n’ont pas atteint une échelle suffisante, et l’écart entre les promesses de l’IA et sa mise en œuvre ne cesse de se creuser, selon une étude historique publiée aujourd’hui lors du CoMotion GLOBAL à Riyad. Le rapport Envisioning the Future of Mobility Powered by AI, élaboré par la MI...
-
Morris & Dickson LLC Signs Letter of Intent to Acquire Prodigy Health
SHREVEPORT, La.--(BUSINESS WIRE)--Morris & Dickson, the nation’s largest independent wholesale and specialty distributor, today announced that it has signed a non-binding Letter of Intent (LOI) to acquire Prodigy Health, a privately held, national specialty distributor of plasma derivatives, specialty drugs and vaccines. The proposed acquisition underscores Morris & Dickson’s accelerated growth in serving both inpatient and outpatient care settings for health systems, hospitals and prov...
-
Un estudio revela que la IA no podrá transformar los sistemas de movilidad si la colaboración entre partes no sale de lo habitual
RIAD, Arabia Saudita--(BUSINESS WIRE)--La inteligencia artificial está transformando los sistemas de transporte globales de manera silenciosa, pero la mayoría de las implementaciones siguen siendo proyectos piloto aislados que no alcanzan escalas significativas, y se amplía la brecha entre las promesas de la IA y su puesta en marcha, según reveló un estudio representativo presentado hoy en CoMotion GLOBAL en Riad. El informe Envisioning the Future of Mobility Powered by AI (Pensar el futuro de...
-
emeis : Programme de rachat de titres
PUTEAUX, France--(BUSINESS WIRE)--Regulatory News: emeis (Paris:EMEIS) : Déclaration des transactions sur actions propres Période du 1 au 5 décembre 2025 Emetteur : EMEIS (LEI : 969500LHIH3NT7PK1V89) Catégories de titres : actions ordinaires (ISIN : FR001400NLM4) Descriptif du programme mis en ligne sur le site Internet de l’Autorité des Marchés Financiers le 8 décembre 2025 Rapport hebdomadaire sur les rachats d'actions du 3 novembre au 7 novembre 2025 Nom de l'émetteur Code identifiant de l...
-
Bank of New York Mellon UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- As Agent Bank, please be advised of the following rate determined on: 12/8/2025 Issue ¦ Gracechurch Card Programme Funding PLC - Series 14 - 2 Class D GBP 286,793,000 FRN due June 2024 ISIN Number ¦ XS1133034253 ISIN Reference ¦ 113303425 Issue Nomin GBP ¦ 286793000 Period ¦ 11/17/2025 to 12/15/2025 Payment Date 12/15/2025 Number of Days ¦ 28 Rate ¦ 8.9757 Denomination GBP ¦ 1000 ¦ 286793000 ¦ Amount Payable per Denomination ¦ 6.89 ¦ 1974704.17 ¦...
-
MaaT Pharma présente les résultats de l’étude pivotale de Phase 3 ARES pour MaaT013 (Xervyteg®) dans la GvH aiguë au Congrès annuel de l’ASH 2025 et annonce 54% de Survie Globale à 1 an
LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, annonce aujourd’hui que le docteur Florent Malard, PhD et professeur d’hématologie à l’Hôpital Saint-Antoine et à Sorbonne Université, et investigateur principal de l’ess...
-
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages DeFi Technologies Inc. (DEFT) Shareholders To Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired DeFi Technologies Inc. (“DeFi” or the “Company”) (NASDAQ: DEFT) securities between May 12, 2025 and November 14, 2025, inclusive (the “Class Period”). DeFi investors have until January 30, 2026 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON YOUR D...
-
Milliman Announces Acquisition of MorVest Capital, Expanding Leadership in Mortgage Sector and MSR Analytics
SEATTLE--(BUSINESS WIRE)--Milliman, Inc., a leading global consulting and actuarial firm, today announced the acquisition of MorVest Capital, a premier provider of mortgage servicing rights (MSR) analytics, risk management, and advisory services. This strategic move reinforces Milliman’s commitment to delivering comprehensive analytical solutions to the mortgage sector and expands its capabilities with MSR valuation, financing, hedging, and brokering. MorVest Capital, founded in 2013 and headqu...
-
MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival
LYON, France--(BUSINESS WIRE)--MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival....